Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance

Emerging Company Profile: Partnered with Novartis on a nanoparticle candidate for type 1 diabetes, Parvus develops its proprietary Navacims to help the body’s immune system differ between a pathogen and itself.

Emerging Company Profile Regular column feature image Version 2

Canadian biotech Parvus Therapeutics Inc. believes it has a revolutionary approach to addressing a host of autoimmune diseases by essentially teaching the patient’s immune system to differentiate between a pathogen and itself so that the innate immune response does not cause off-target damage along with its therapeutic benefits.

Based in Calgary, Parvus stems from the research of Pere Santamaria, now the firm’s chief scientific officer and a board member. The biotech got a vital vote of confidence in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By 

New CEO Renée Aguiar-Lucander is marking her mark.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By 

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

More from Business

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.